Scotiabank raised the firm’s price target on Bionano Genomics (BNGO) to $4 from $1 and keeps a Sector Perform rating on the shares. Despite the challenging macroeconomic environment in 2024, there were “bright spots” for the company, such as double-digit growth for Consumables and Software revenues, the analyst tells investors. The firm is favoring the sidelines until it has better visibility into the company’s near- to medium-term growth potential.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNGO:
- Bionano Genomics Q4 Earnings Call: Mixed Sentiments and Strategic Shifts
- Bionano Genomics Reports 2024 Financial Results
- Bionano Genomics reports Q4 revenue $8.16M vs. $10.72M last year
- Bionano Genomics announces publication on study using OGM
- Bionano Genomics announces publication reporting first use of OGM to detect CAG
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue